Blood Immune Cells After Bone Marrow Transplant for Leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that is not secondary to another condition
- Your leukemia is in complete remission (no signs of cancer) before transplant
- You are able to perform daily activities with minimal help (Karnofsky score 80% or higher)
- You will receive stem cells from your own blood (peripheral blood stem cells), not bone marrow
- You have never had a stem cell transplant before
- Your cancer is controlled and not actively progressing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at changes in your immune cells (T cells) in people with acute myeloid leukemia (AML) who are scheduled for a donor stem cell transplant. It may help doctors better understand how the immune system responds during and after transplant.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This study tests a new blood test to help predict whether acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will come back after a stem cell transplant. Early detection could help doctors treat relapse sooner.
This study looks at how the immune system changes after an allogeneic stem cell transplant (using a donor’s stem cells). It may help researchers understand what controls immune recovery and transplant-related complications.
This study collects blood samples from patients who have survived at least 3 months after a stem cell transplant to identify markers that could predict chronic graft-versus-host disease (a condition where the transplanted cells attack the body). The goal is to develop a simple blood test that could help doctors catch and treat this complication earlier.
Hear when a new Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.